Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822473 | 0.92 | CYP3A4 (0.73) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL12605147 | 0.92 | CYP3A4 (0.75) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL12561540 | 0.91 | CYP3A4 (0.74) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1817562 | 0.90 | CYP3A4 (0.78) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1820020 | 0.90 | CYP3A4 (0.72) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1816831 | 0.89 | CYP3A4 (0.71) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL18712290 | 0.88 | CYP3A4 (0.75) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1816744 | 0.88 | CYP3A4 (0.72) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1817824 | 0.88 | CYP3A4 (0.74) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1816548 | 0.87 | CYP3A4 (0.69) | CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | claimed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | CYP3A4 2604/4885CYP2C19 2391/4885CYP2C9 2207/4885 |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, KRAS, RAF1 | CYP3A4 2604/4885CYP2C19 2391/4885CYP2C9 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.